XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in ...

This was a study led by Dr. Pallawi Torka from Memorial Sloan Kettering that we participated in, where they performed as a ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...